a public good project by the
Synthesis
Company
of California

© 2026

L-Asparaginase—Based Regimen in the Treatment of Refractory Midline Nasal/Nasal-Type T/NK-Cell Lymphoma | doi.page

0 citations0 references

Google Scholar doi.org

L-Asparaginase—Based Regimen in the Treatment of Refractory Midline Nasal/Nasal-Type T/NK-Cell Lymphoma

International Journal of Hematology·2003·Vol. 78(2), pp. 163–167

Citations Over TimeTop 21% of 2003 papers

Weiben Yong, Wen Zheng, Yuntao Zhang, Jun Zhu, Wei Yan, Deliang Zhu, Jiyou Li

Related Papers

→ Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles(2013)546 cited
→ CHOP chemotherapy for the treatment of canine multicentric T‐cell lymphoma(2010)106 cited
Expression of hypoxia-inducible factor-1a predicts benefit from rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.(2018)
Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma. An update of the GELA study.(2001)
→ B-Cell Lymphoma With Intermediate- to High-Grade Features and Different Immunophenotypic Profiles Involving Separate Anatomic Sites With a Good Response to R-CHOP(2009)